SLC5A2 and chronic kidney disease: Clinical trials of SGLT-2 inhibition conducted in populations with CKD have continued SGLT-2 inhibition until the initiation of kidney replacement therapy, providing indirect evidence to support the use of this SGLT-2 inhibition in this population [1–3].